117 related articles for article (PubMed ID: 26320506)
1. Meta-Analysis of Circulating Endothelial Cells and Circulating Endothelial Progenitor Cells as Prognostic Factors in Lung Cancer.
Yu M; Men HT; Niu ZM; Zhu YX; Tan BX; Li LH; Jiang J
Asian Pac J Cancer Prev; 2015; 16(14):6123-8. PubMed ID: 26320506
[TBL] [Abstract][Full Text] [Related]
2. Predictive and prognostic significance of circulating endothelial cells in advanced non-small cell lung cancer patients.
Yuan DM; Zhang Q; Lv YL; Ma XQ; Zhang Y; Liu HB; Song Y
Tumour Biol; 2015 Nov; 36(11):9031-7. PubMed ID: 26084612
[TBL] [Abstract][Full Text] [Related]
3. Meta-analysis of circulating tumor cells as a prognostic marker in lung cancer.
Ma XL; Xiao ZL; Liu L; Liu XX; Nie W; Li P; Chen NY; Wei YQ
Asian Pac J Cancer Prev; 2012; 13(4):1137-44. PubMed ID: 22799295
[TBL] [Abstract][Full Text] [Related]
4. Circulating endothelial cells as a biomarker in non-small cell lung cancer patients: correlation with clinical outcome.
Najjar F; Alammar M; Bachour M; Al-Massarani G
Int J Biol Markers; 2014 Dec; 29(4):e337-44. PubMed ID: 25041783
[TBL] [Abstract][Full Text] [Related]
5. Circulating endothelial cells and microparticles for prediction of tumor progression and outcomes in advanced non-small cell lung cancer.
Najjar F; Alammar M; Al-Massarani G; Almalla N; Aljapawe A; Ikhtiar A
Cancer Biomark; 2017 Sep; 20(3):333-343. PubMed ID: 28800312
[TBL] [Abstract][Full Text] [Related]
6. Circulating endothelial cells and microparticles as diagnostic and prognostic biomarkers in small-cell lung cancer.
Najjar F; Alammar M; Al-Massarani G; Almalla N; Japawe A; Ikhtiar A
Lung Cancer; 2018 Oct; 124():23-30. PubMed ID: 30268466
[TBL] [Abstract][Full Text] [Related]
7. Circulating endothelial cells in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
Kawaishi M; Fujiwara Y; Fukui T; Kato T; Yamada K; Ohe Y; Kunitoh H; Sekine I; Yamamoto N; Nokihara H; Watabe T; Shimoda Y; Arao T; Nishio K; Tamura T; Koizumi F
J Thorac Oncol; 2009 Feb; 4(2):208-13. PubMed ID: 19179898
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016.
Ikeda S; Kato T; Ogura T; Sekine A; Oda T; Masuda N; Igawa S; Katono K; Otani S; Yamada K; Saito H; Kondo T; Hosomi Y; Nakahara Y; Nishikawa M; Utumi K; Misumi Y; Yamanaka T; Sakamaki K; Okamoto H
BMC Cancer; 2018 Mar; 18(1):241. PubMed ID: 29499653
[TBL] [Abstract][Full Text] [Related]
9. Circulating tumor cells predict survival benefit from chemotherapy in patients with lung cancer.
Wu ZX; Liu Z; Jiang HL; Pan HM; Han WD
Oncotarget; 2016 Oct; 7(41):67586-67596. PubMed ID: 27588489
[TBL] [Abstract][Full Text] [Related]
10. The endothelial status reflected by circulating endothelial cells, circulating endothelial progenitor cells and soluble thrombomodulin in patients with mild and resistant hypertension.
Budzyń M; Gryszczyńska B; Boruczkowski M; Kaczmarek M; Begier-Krasińska B; Osińska A; Bukowska A; Iskra M; Kasprzak MP
Vascul Pharmacol; 2019 Feb; 113():77-85. PubMed ID: 30590133
[TBL] [Abstract][Full Text] [Related]
11. The evaluation of circulating endothelial progenitor cells and related angiogenic markers as prognostic factors in soft-tissue tumors.
Karampinis I; Joas E; Dreyer A; Ronellenfitsch U; Jakob J; Hohenberger P; Nowak K
Eur J Surg Oncol; 2018 Apr; 44(4):496-501. PubMed ID: 29397265
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of pretreatment platelet counts in lung cancer: a systematic review and meta-analysis.
Yuan Y; Zhong H; Ye L; Li Q; Fang S; Gu W; Qian Y
BMC Pulm Med; 2020 Apr; 20(1):96. PubMed ID: 32312252
[TBL] [Abstract][Full Text] [Related]
13. Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer.
Chakra M; Pujol JL; Lamy PJ; Bozonnat MC; Quantin X; Jacot W; Daurès JP
J Thorac Oncol; 2008 Oct; 3(10):1119-26. PubMed ID: 18827607
[TBL] [Abstract][Full Text] [Related]
14. Can determination of circulating endothelial cells and serum caspase-cleaved CK18 predict for response and survival in patients with advanced non-small-cell lung cancer receiving endostatin and paclitaxel-carboplatin chemotherapy? a retrospective study.
Chu TQ; Ding H; Garfield DH; Gu AQ; Pei J; Du WD; Han BH
J Thorac Oncol; 2012 Dec; 7(12):1781-1789. PubMed ID: 23154549
[TBL] [Abstract][Full Text] [Related]
15. Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.
Ostheimer C; Evers C; Bache M; Reese T; Vordermark D
Strahlenther Onkol; 2018 Jun; 194(6):539-551. PubMed ID: 29340706
[TBL] [Abstract][Full Text] [Related]
16. Circulating tumor cells prior to initial treatment is an important prognostic factor of survival in non-small cell lung cancer: a meta-analysis and system review.
Jiang SS; Deng B; Feng YG; Qian K; Tan QY; Wang RW
BMC Pulm Med; 2019 Dec; 19(1):262. PubMed ID: 31878900
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and clinicopathological significance of circulating tumor cells detected by RT-PCR in non-metastatic colorectal cancer: a meta-analysis and systematic review.
Yang C; Zou K; Zheng L; Xiong B
BMC Cancer; 2017 Nov; 17(1):725. PubMed ID: 29115932
[TBL] [Abstract][Full Text] [Related]
18. Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study.
Salgia R; Weaver RW; McCleod M; Stille JR; Yan SB; Roberson S; Polzer J; Flynt A; Raddad E; Peek VL; Wijayawardana SR; Um SL; Gross S; Connelly MC; Morano C; Repollet M; Sanders R; Baeten K; D'Haese D; Spigel DR
Invest New Drugs; 2017 Jun; 35(3):334-344. PubMed ID: 28299514
[TBL] [Abstract][Full Text] [Related]
19. A prospective study of the use of circulating markers as predictors for epidermal growth factor receptor-tyrosine kinase inhibitor treatment in pulmonary adenocarcinoma.
Luo YH; Tseng PC; Lee YC; Perng RP; Whang-Peng J; Chen YM
Cancer Biomark; 2016; 16(1):19-29. PubMed ID: 26484608
[TBL] [Abstract][Full Text] [Related]
20. Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis.
Cargnin S; Canonico PL; Genazzani AA; Terrazzino S
J Thorac Oncol; 2017 Jan; 12(1):43-53. PubMed ID: 27543256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
